BTX - Brooklyn ImmunoTherapeutics stock down ~12% after Q4 2021 results

Shares of Brooklyn ImmunoTherapeutics (NASDAQ:BTX) have fallen 11.9% on Monday in afternoon trading, after the clinical-stage biopharmaceutical company reported on April 15 its Q4 and FY 2021 results. BTX stock has lost ~61% YTD as of last close, snapping a six-session losing streak only last week. The company last month announced a $12M equity offering. BTX said it posted a Q4 GAAP EPS of -$0.16, compared to -$1.22 for the prior year quarter. The company's Q4 R&D expenses more than doubled to $4.2M, primarily due to increased license fees and non-cash stock-based compensation resulting from the issuance of equity awards. BTX's most advanced program is IRX-2, a human cell-derived cytokine therapy currently undergoing studies for the treatment of several types of cancer. "As we await the readout of our Phase 2b trial for neoadjuvant head and neck cancer with our original asset, IRX-2, during (Q2 2022), we continue investigator-driven trials

For further details see:

Brooklyn ImmunoTherapeutics stock down ~12% after Q4 2021 results